More news – Page 14
-
NewsLilly bolsters leadership team with neuroscience and immunology in mind
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
-
News
Galapagos set for small molecule and biologics pivot after cell therapy exit
But the Belgium biotech’s decision to winddown the cell business will cause it to cut around 90 percent of its headcount.
-
NewsThermally driven chemical reaction shows drug manufacturing promise
The “simple” approach for initiating electron transfer reactions could enable synthesis of small molecule drugs, researchers say.
-
NewsMHRA selects Prof Jacob George as its first Chief Medical and Scientific Officer
The cardiovascular expert will head the UK medicines regulator’s science and innovation strategies.
-
NewsChiesi completes expansion of French metered dose inhaler facility
The enlarged La Chaussée-Saint-Victor site will serve as a manufacturing hub for the biopharma company.
-
News
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility
The €2.6 billion manufacturing investment complements the recent US manufacturing expansion for its next potential blockbuster obesity treatment orforglipron.
-
NewsHovione doubles spray drying capacity with $100m US investment round
The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet.
-
NewsCPHI Europe adds AI and tech zone for its return to Milan in 2026
Following 2025’s event in Frankfurt, Informa’s flagship pharma exhibition will next year include an area for artificial intelligence.
-
NewsMHRA set to overhaul the UK’s rare disease drug regulatory pathway
The medicines regulator will aim to take a more flexible licensing approach for the research and manufacture of rare disease therapies in the UK.
-
News
Pfizer and Novo Nordisk battle for obesity market dominance
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
-
News
AI reshapes pharma recruitment, but skills gaps, culture and bias temper gains
Cultural change inside pharma needed to help attract tech talent and support a deeper adoption of AI in the industry, say recruiters at CPHI Frankfurt 2025.
-
News
FDA draft guidance on biosimilars offers “regulatory relief”
US agency follows in footsteps of European Medicines Agency (EMA) in efforts to streamline biosimilar development.
-
NewsRaman-based PAT tool could advance continuous vaccine manufacturing
Study demonstrates the non-invasive tool’s potential for real-time monitoring of cytomegalovirus (CMV) viral particles.
-
News
CPHI Pharma Awards 2025 reward Fujifilm, RezonBio and Esteve leaders
Winners at the ceremony in Frankfurt also included CNX Therapeutics, NunaBio, Evonik Industries and Corden Pharma.
-
NewsAI expert warns pharma industry: artificial intelligence is a competitor, not just a tool
Speaking at CPHI Frankfurt, Bruno Fabre underlined the importance of companies viewing the technology as a fundamental business capability, rather than “an afterthought”.
-
News
Lilly AI factory to accelerate pharmaceutical manufacturing and development
Pharma giant plans to harness its “decades of data” and use AI to set a new scientific standard that accelerates pharmaceutical innovation.
-
NewsTaiwan talks evidence-driven TCM at CPHI Frankfurt
Scientific and commercial opportunity for pharma companies looking to source, co develop and manufacture traditional Chinese medicine (TCM).
-
NewsAxplora talks reliability-first investments to secure API supply
The CDMO’s programme, presented at CPHI Frankfurt 2025, combines responsiveness to new demand and operational rigour without jeopardising supply.
-
NewsEnsera talks integrated design-to-manufacture model at CPHI Frankfurt 2025
Model offers mid market innovators and larger pharma companies tailored processes and scale capacity without compromising compliance.
-
NewsSirolimus-eluting balloon offers potential “paradigm shift” in restenosis treatment
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.